Cargando…

Corrigendum: Cost per response analysis of repository corticotropin injection versus other alternative treatments for acute exacerbations of multiple sclerosis

The authors wish to make the following corrections to their article:

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioExcel Publishing Ltd 2021
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839944/ https://www.ncbi.nlm.nih.gov/pubmed/33542740 http://dx.doi.org/10.7573/dic.2020-12-11

Ejemplares similares

Cost per response analysis of repository corticotropin injection versus other alternative treatments for acute exacerbations of multiple sclerosis
por: Wan, George J, et al.
Publicado: (2020)

Cost-Effectiveness of Repository Corticotropin Injection for the Treatment of Acute Exacerbations in Multiple Sclerosis
por: Hunter, Samuel F, et al.
Publicado: (2021)

Consequences of Insurance Denials Among U.S. Patients Prescribed Repository Corticotropin Injection for Acute Exacerbations of Multiple Sclerosis
por: Rice, J. Bradford, et al.
Publicado: (2020)

H.P. Acthar Gel (repository corticotropin injection) treatment of patients with multiple sclerosis and diabetes
por: Kutz, Christen
Publicado: (2016)

Cost-Effectiveness of Repository Corticotropin Injection versus Standard of Care for the Treatment of Active Rheumatoid Arthritis
por: Bindra, Jas, et al.
Publicado: (2021)

A Prospective Observational Registry of Repository Corticotropin Injection (Acthar® Gel) for the Treatment of Multiple Sclerosis Relapse
por: Kaplan, Jeffrey, et al.
Publicado: (2020)

Repository Corticotropin Injection for Treatment of Idiopathic Inflammatory Myopathies
por: Patel, Aarat, et al.
Publicado: (2016)

Treatment of fibrillary glomerulonephritis with use of repository corticotropin injections
por: Maroz, Natallia, et al.
Publicado: (2018)

Corrigendum to “Rituximab versus mitoxantrone: comparing effectiveness and safety in advanced relapsing multiple sclerosis”
Publicado: (2021)

Corrigendum to Serum hepcidin levels in multiple sclerosis
Publicado: (2020)

Repository corticotropin injection in patients with rheumatoid arthritis resistant to biologic therapies
por: Fischer, Peter A, et al.
Publicado: (2018)

Treatment of Noninfectious Retinal Vasculitis Using Subcutaneous Repository Corticotropin Injection
por: Anesi, Stephen D., et al.
Publicado: (2021)

Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis: A Narrative Review
por: Mirsaeidi, Mehdi, et al.
Publicado: (2022)

COPD management costs according to the frequency of COPD exacerbations in UK primary care [Corrigendum]
Publicado: (2014)

Repository corticotropin for Chronic Pulmonary Sarcoidosis
por: Baughman, Robert P., et al.
Publicado: (2017)

Repository corticotropin injection in patients with refractory psoriatic arthritis: a case series
por: Brown, Alan N
Publicado: (2016)

Real-world treatment patterns for repository corticotropin injection in patients with rheumatoid arthritis
por: Busch, Howard, et al.
Publicado: (2022)

A Narrative Review of Repository Corticotropin Injection for the Treatment of Systemic Lupus Erythematosus
por: Askanase, Anca D., et al.
Publicado: (2022)

Corrigendum to miRNAs in Microglia: Important Players in Multiple Sclerosis Pathology
Publicado: (2022)

Corrigendum: Brain network correlates of epilepsy occurrence in multiple sclerosis and neuroinflammation
Publicado: (2023)

Repository corticotropin injection in patients with advanced symptomatic sarcoidosis: retrospective analysis of medical records
por: Chopra, Ishveen, et al.
Publicado: (2019)

Repository Corticotropin Injections Promote Clinical Remission and Regulatory T Cell Expansion in Membranous Nephropathy
por: Hartzell, Susan, et al.
Publicado: (2021)

CORRIGENDUM to Risk of Cancer in a Community Exposed to Per- and Poly-Fluoroalkyl Substances
Publicado: (2022)

Corrigendum to “Cost-Effectiveness of the Aerobika® Oscillating Positive Expiratory Pressure Device in the Management of Chronic Obstructive Pulmonary Disease Exacerbations in Canada”
por: Thanh, Nguyen Xuan, et al.
Publicado: (2019)

Repository corticotropin injection versus corticosteroids for protection against renal damage in a focal segmental glomerulosclerosis rodent model
por: Hayes, Kyle, et al.
Publicado: (2020)

CORRIGENDUM to Progressive multifocal leukoencephalopathy outcomes in patients with multiple sclerosis treated with dimethyl fumarate
Publicado: (2023)

Nasal high-flow in acute hypercapnic exacerbation of COPD [Corrigendum]
Publicado: (2019)

Repetitive Saliva Swallowing Test Predicts COPD Exacerbation [Corrigendum]
Publicado: (2021)

Results from a multicenter, randomized, double‐blind, placebo‐controlled study of repository corticotropin injection for multiple sclerosis relapse that did not adequately respond to corticosteroids
por: Wynn, Daniel, et al.
Publicado: (2022)

Corrigendum to “A Longitudinal Examination of the Hopelessness Theory of Depression in People Who Have Multiple Sclerosis”
por: Kneebone, I. I., et al.
Publicado: (2020)

Pharmacodynamics and tolerability of repository corticotropin injection in healthy human subjects: A comparison with intravenous methylprednisolone
por: Lal, Ritu, et al.
Publicado: (2015)

Treatment with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Dermatomyositis/Polymyositis
por: Ho-Mahler, Nancy, et al.
Publicado: (2020)

Understanding Predictors of Response to Repository Corticotropin Injection Treatment Among Patients With Advanced Symptomatic Sarcoidosis
por: Bindra, Jas, et al.
Publicado: (2022)

Predicting frequent COPD exacerbations using primary care data [Corrigendum]
Publicado: (2018)

The Relationship Between Morning Symptoms and the Risk of Future Exacerbations in COPD [Corrigendum]
Publicado: (2021)

Cost analysis of pulmonary lobectomy procedure: comparison of stapler versus precision dissection and sealant [Corrigendum]
Publicado: (2018)

Correction to: Repository corticotropin injection versus corticosteroids for protection against renal damage in a focal segmental glomerulosclerosis rodent model
por: Hayes, Kyle, et al.
Publicado: (2020)

Treatment of a multiple sclerosis animal model by a novel nanodrop formulation of a natural antioxidant [Corrigendum]
Publicado: (2018)

Multimodal intervention improves fatigue and quality of life in subjects with progressive multiple sclerosis: a pilot study [Corrigendum]
Publicado: (2015)

Medical resource utilization in dermatomyositis/polymyositis patients treated with repository corticotropin injection, intravenous immunoglobulin, and/or rituximab
por: Knight, Tyler, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_pgfov153470avurvu2psoqseob